Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:09:00.019Z.
Consensus retrieved: 2026-10-06T14:42:33.120Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:09:00.019Z.
Quote observation: 2026-10-06T16:05:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4ee4545eb4fe5103374f291c717036760539f0ddea1c9b76c24efb1a2679ece0
Forward PE Ratio (N/A) = Dated Quote Price ($19.57) / Consensus Forward EPS ($-5.89)
FORWARD PE RATIO
N/A
Odyssey Therapeutics, Inc.
Market Cap
$939.97M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Odyssey Therapeutics, Inc. (ODTX) | $939.97M | N/A |
| CeriBell, Inc. (CBLL)vs › | $933.58M | N/A |
| MoonLake Immunotherapeutics (MLTX)vs › | $949.28M | N/A |
| Kura Oncology, Inc. (KURA)vs › | $955.57M | N/A |
| HealthStream, Inc. (HSTM)vs › | $912.88M | 42.34 |
| Bioventus Inc. (BVS)vs › | $897.98M | 17.02 |
| Arbutus Biopharma Corp (ABUS)vs › | $897.81M | 6.14 |
| Aktis Oncology, Inc. (AKTS)vs › | $983.49M | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $988.00M | N/A |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $887.99M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $19.57, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-5.89 | $-6.95 – $-5.17 | 4 | n/m |
| 2027-12-31 | $-4.87 | $-6.65 – $-3.45 | 4 | n/m |
| 2028-12-31 | $-4.83 | $-5.70 – $-3.58 | 6 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
